Substance abuse treatment in human immunodeficiency virus: The role of patient–provider discussions

{ "0" : "Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA" , "1" : "Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA" , "2" : "Agency for Healthcare Research and Quality, Rockville, MD 20850, USA" , "3" : "Community Medical Alliance, Boston, MA 02210, USA" , "4" : "Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21201, USA" , "6" : "HIV" , "7" : "Communication" , "8" : "Health services accessibility" , "9" : "African Americans" , "10" : "Substance-related disorders" , "11" : "Transportation"}
Journal of substance abuse treatment (Impact Factor: 2.9). 10/2008; 35(3):294-303. DOI: 10.1016/j.jsat.2007.11.005

ABSTRACT Substance abuse treatment is associated with decreases in human immunodeficiency virus (HIV) risk behavior and can improve HIV outcomes. The purpose of this study was to examine factors associated with substance abuse treatment utilization, including patient–provider discussions of substance use issues. We surveyed 951 HIV-infected adults receiving care at 14 HIV Research Network primary care sites regarding drug and alcohol use, substance abuse treatment, and provider discussions of substance use issues. Although 71% reported substance use, only 24% reported receiving substance abuse treatment and less than half reported discussing substance use issues with their HIV providers. In adjusted logistic regression models, receipt of substance abuse treatment was associated with patient–provider discussions. Patient–provider discussions of substance use issues were associated with current drug use, hazardous or binge drinking, and Black race or ethnicity, though substance use was comparable between Blacks and Whites. These data suggest potential opportunities for improving engagement in substance abuse treatment services.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Background and Objectives Mental health clinicians have an important opportunity to help depression patients reduce co-occurring alcohol and drug use. This study examined demographic and clinical patient characteristics and service factors associated with receiving a recommendation to reduce alcohol and drug use from providers in a university-based outpatient psychiatry clinic.Methods The sample consisted of 97 participants ages 18 and older who reported hazardous drinking (≥3 drinks/occasion), illegal drug use (primarily cannabis) or misuse of prescription drugs, and who scored ≥15 on the Beck Depression Inventory-II (BDI-II). Participants were interviewed at intake and 6 months.ResultsAt 6-month telephone interview, 30% of participants reported that a clinic provider had recommended that they reduce alcohol or drug use. In logistic regression, factors associated with receiving advice to reduce use included greater number of drinks consumed in the 30 days prior to intake (p = .035); and greater depression severity on the BDI-II (p = .096) and hazardous drinking at 6 months (p = .05).Conclusions and Scientific SignificanceWhile participants with greater alcohol intake and depression symptom severity were more likely to receive advice to reduce use, the low overall rate of recommendation to reduce use highlights the need to improve alcohol and drug use intervention among depression patients, and potentially to address alcohol and drug training and treatment implementation issues among mental health providers. (Am J Addict 2014;XX:XX–XX)
    American Journal on Addictions 08/2014; 23(6). DOI:10.1111/j.1521-0391.2014.12140.x · 1.74 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: 23.1 million individuals meet the diagnostic criteria for a substance use disorder and are in need of treatment, yet only about 10% receive treatment. Risk behaviors for HIV among illicit drug users are endemic. Less than half of AOD treatment programs offer testing for HIV or STIs. Methods: Data were from 1189 respondents who reported using 1 or more illicit drugs in the past 30 days and were sampled in the Countywide Risk Assessment Survey (CRAS) conducted by 51 HIV prevention contractors in Los Angeles County CA. Results: A logistic regression model determined that those respondents who accessed drug treatment were more likely to: use a needle exchange, use mental health, HIV, and STD treatment services. They were also more likely to be involved with child welfare. Those who accessed AOD treatment had more concurrent sex partners and used a greater number of drugs, particularly heroin, methamphetamine, and crack cocaine, than those who did not. They were also more likely to be HIV+. Conclusions: This analysis of data from a community-based sample of illicit drug users found further evidence of the critical importance of integrating AOD treatment and HIV services. Findings also indicate a need to screen for STIs among those accessing AOD treatment and to focus on safer sex practices regarding concurrent relationships. Mental health and child welfare agencies were found to be potential linkage points for HIV prevention services.
    140st APHA Annual Meeting and Exposition 2012; 10/2012
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hospitals seem to be places where harm reduction approaches could have great benefit but few have responded to the needs of people who use drugs. Drawing on recent theoretical contributions to harm reduction from health geography, we examine how the implementation of harm reduction is shaped by space and contested understandings of place and health. We examine how drug use and harm reduction approaches pose challenges and offer opportunities in hospital-based care using interview data from people living with HIV and who were or had recently been admitted to a hospital with an innovative harm reduction policy. Our data reveal the contested spatial arrangements (and the related practices and corporeal relations) that occur due to the discordance between harm reduction and hospital regulatory policy. Rather than de-stigmatizing drug use at Casey House Hospital, the adoption of the harm reduction policy sparked inter-client conflict, reproduced dominant discourses about health and drug users, and highlights the challenges of sharing space when drug use is involved. The hospital setting produces particular ways of being for people who use and those who do not use drugs and the demarcation of space in a drug using context. Moving forward, harm reduction practice and research needs to consider more than just interactions between drug users and healthcare providers, or the role of administrative policies; it needs to position ethics at the forefront of understanding the collisions between people, drug use, place, and space. We raise questions about the relationship between subjectivity and spatial arrangements in mediating the success of harm reduction.
    The International journal on drug policy 05/2014; 25(3). DOI:10.1016/j.drugpo.2014.02.012 · 2.54 Impact Factor